Baseline characteristics of participants in phase I clinical trial
| Characteristics | Stage I (18–50 years) | Stage II (51–75 years) | |||
| Placebo (N=8) | 3 µg (N=24) | 5 µg (N=24) | Placebo (N=8) | 5 µg (N=24) | |
| Sex (N, %) | |||||
| Female | 4 (50.0) | 10 (41.7) | 6 (25.0) | 4 (50.0) | 11 (45.8) |
| Male | 4 (50.0) | 14 (58.3) | 18 (75.0) | 4 (50.0) | 13 (54.2) |
| Age (mean-SD) | 34.4 (7.8) | 34.0 (8.6) | 35.0 (6.8) | 55.5 (3.5) | 58.5 (6.9) |
| Baseline vital signs (mean-SD) | |||||
| Body temperature (°C) | 36.8 (0.4) | 36.6 (0.2) | 36.5 (0.2) | 36.7 (0.2) | 35.2 (7.5) |
| Respiratory rate (per minute) | 16.1 (1.3) | 15.9 (1.0) | 15.6 (0.5) | 15.3 (0.9) | 14.5 (3.2) |
| Heart rate (beats per minute) | 89.9 (3.1) | 82.9 (9.3) | 86.7 (6.8) | 81.0 (12.9) | 79.0 (18.9) |
| Systolic blood pressure (mm Hg) | 120.6 (11.6) | 119.7 (11.7) | 118.6 (10.6) | 124.9 (8.5) | 120.0 (26.3) |
| Diastolic blood pressure (mm Hg) | 79.6 (10.4) | 77.2 (9.6) | 77.5 (6.5) | 81.5 (4.0) | 77.8 (17.0) |